It’s 1963. Professor Raphael Mechoulam becomes the first scientist to isolate and synthesize the active components of the cannabis plant. Which ones? THC, CBD, and several other cannabinoids. Later, in 1988, he makes headlines again. His laboratory discovers the endocannabinoid system (ECS). All these contributions to the advancement of cannabis science make Raphael Mechoulam the “godfather” of research in this field. In fact, his discoveries have shaped and transformed the world of medical research related to cannabis. Summary Another line on the genius’s CV! An even larger elite of geniuses Reassuring scientific data! Another line on the genius’s CV!
In fact, the professor is still at work. Indeed, this genius leads the EPM medical team. The company plans to list on the Tel Aviv Stock Exchange towards the end of 2021.
- The medical team’s research aims to explore the potential of cannabis acids as an alternative medicine for several diseases, including Crohn’s disease, colitis, and epilepsy. To this end, the team has replicated the structures of cannabis acids, enabling their large-scale reproduction without the need for living plants. EPM CEO Reshef Swisa, in an interview with the Jerusalem Post, stated:
- “We have developed 14 different molecules so far, eight of which are completely new discoveries. This means we hold a very exclusive patent on them, as they represent a new discovery for the scientific community.” Swisa added:
“Each of these molecules has the potential to be developed into multiple medications, while many companies can do incredible things with even a single molecule.”
An even larger elite of geniuses Indeed, these researchers are not the only ones exploring the potential of plants in this field. In fact,Swisa
cited the example of the epilepsy drug Epidiolex, which British pharmaceutical businessman
Julian Gangolli helped launch. The drug became the first cannabis derivative approved by the FDA in 2018. Gangolli explains:
“We had children who were having 40 or 50 epileptic seizures a week, which this product was able to reduce to very few, if any, seizures.”
There are others of this type. In fact, many medications come from plants. This is the case with aspirin, which is a synthetic version of salicylic acid, derived from willow bark. Reassuring scientific data! The data already available is increasingly reassuring patients. Indeed,
Swisa
stated that their tests for colitis showed that synthesized cannabis acids outperform CBD treatments. Furthermore, these acids work in the same way as standard treatments and steroids on the market. This discovery is quite significant. Why? Because steroids have a number of side effects, including a weakening of the immune system. In this vein,
Swisa explains: “The more we investigated, the more we saw that we have a potential new alternative for probably two of the most horrific diseases you can find today.”
They continue:
“Crohn’s disease and colitis are life-destroying. Right now, people are forced to choose between the bad and the terrible.”
Furthermore, EPM has discovered that synthetic cannabis acids have the potential to treat obesity, lung inflammation, nausea, depression, anxiety, and skin conditions such as psoriasis and atopic dermatitis.
